Nandrolone vs Turinabol
FDA Approved vs Moderate Research
avoid Mechanism-based · 64% Both Nandrolone and Turinabol carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Nandrolone Turinabol
Weight 274.40 Da (base) 334.88 Da
Half-life ~6-12 days (decanoate) ~16 hours
Type 19-nortestosterone steroid (C18H26O2) 17-alpha-alkylated anabolic-androgenic steroid (C20H27ClO2)
Key Benefits
Nandrolone
01 Significant increases in lean muscle mass with a favorable anabolic-to-androgenic ratio
02 Enhanced collagen synthesis and joint lubrication, reducing joint pain and improving connective tissue integrity
03 Increased bone mineral density through direct osteoblast stimulation
04 Improved nitrogen retention and protein synthesis for accelerated recovery
05 Stimulation of erythropoietin production, increasing red blood cell mass and oxygen delivery
06 Lower androgenic side effects (hair loss, acne, prostate enlargement) compared to testosterone
07 Clinically demonstrated efficacy in treating anemia of chronic renal failure
08 Potential neuroprotective properties observed in preclinical research
Turinabol
01 Promotes lean, dry muscle gains without water retention or bloating
02 Does not aromatize to estrogen, eliminating risk of gynecomastia and estrogen-related side effects
03 Favorable anabolic-to-androgenic ratio, reducing androgenic side effects relative to muscle-building potential
04 Enhances muscular endurance and recovery through increased red blood cell production
05 Increases strength without significant body weight gain, beneficial for weight-class athletes
06 Improves creatine phosphate resynthesis, supporting repeated high-intensity efforts
07 Relatively mild androgenic profile compared to most oral anabolic steroids
08 Produces slow, steady, maintainable gains rather than rapid temporary increases
Dosing Protocols
Nandrolone
100-200 mg/week (therapeutic) / 1x per week (decanoate) or 2-3x per week (NPP)
TRT Adjunct - Joint Support 50-100 mg/week 1x per week (decanoate)
Therapeutic - Anemia / Wasting 100-200 mg/week 1x per week (decanoate)
Performance Enhancement - Moderate 200-400 mg/week 1x per week (decanoate) or split into 2 injections
NPP Protocol - Shorter Cycle 200-350 mg/week Every other day or 3x per week
Turinabol
30-60 mg/day (male) / Split into 2 doses daily (morning and evening)
Side Effects
Nandrolone
Suppression of natural testosterone production (profoundly suppressive, more so than testosterone alone)
Water retention and bloating (less than testosterone at equianabolic doses)
Erectile dysfunction and reduced libido without concurrent testosterone ('deca dick')
Increased appetite and weight gain
Mild acne and oily skin (less pronounced than testosterone)
Elevated hematocrit and hemoglobin (erythrocytosis)
Injection site pain or discomfort
Mild mood changes (some users report increased emotional sensitivity)
Turinabol
Hepatic stress with elevated liver enzymes (ALT, AST) -- moderate severity, dose- and duration-dependent
HDL cholesterol suppression (significant, often 30-50% reduction)
LDL cholesterol elevation
Suppression of endogenous testosterone production via HPG axis negative feedback
Mild gastrointestinal discomfort or nausea
Back pumps (lower back tightness during exercise, common with 17-alpha-alkylated compounds)
Oily skin and mild acne
Decreased appetite in some users
Contraindications
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy (Category X - causes virilization of female fetus)
Nephrosis or the nephrotic phase of nephritis
Severe hepatic impairment
Hypercalcemia
Known hypersensitivity to nandrolone or any formulation components
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled heart failure or severe cardiovascular disease
Known or suspected prostate cancer
Breast cancer in males
Pregnancy or planned pregnancy (teratogenic risk)
Active liver disease or significant hepatic impairment
Pre-existing severe dyslipidemia or cardiovascular disease
Hypersensitivity to turinabol or related compounds
Research Evidence
Nandrolone Turinabol
Status FDA Approved Moderate Research
References 5 studies 5 studies
Latest April 2005 June 2023
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.